Edgewise Therapeutics reported a net loss of $50.2 million for the fourth quarter of 2025 and a net loss of $167.8 million for the full year, a widening of losses compared with the $39.7 million Q4 loss and $133.8 million full‑year loss reported for 2024. Cash, cash equivalents and marketable securities totaled $530.1 million as of December 31, 2025, giving the company a runway of roughly 12.6 quarters at an average quarterly net loss of $41.95 million.
The company’s earnings per share reflected the broader loss trend. For Q4 2025, the company posted a loss of $0.47 per share versus analysts’ consensus of a $0.43 loss, a miss of $0.04. In Q3 2025, the loss was $0.39 per share, slightly better than the expected $0.40 loss, a beat of $0.01. The modest miss in Q4 was driven by higher than anticipated research and development and general and administrative expenses, while the Q3 beat was largely due to tighter cost control in certain clinical trial operations.
Edgewise’s pipeline remains a key focus. The company continues to advance the GRAND CANYON trial of sevasemten, with top‑line data expected in the fourth quarter of 2026. The CIRRUS‑HCM Phase 2 study of EDG‑7500 is also progressing, with Part D data slated for the first half of 2026. "Following strong execution in 2025, we have entered a transformative year," said Kevin Koch, Ph.D., President and Chief Executive Officer. "We remain on track to deliver pivotal GRAND CANYON top‑line data for sevasemten, with the potential to support the first marketing application for the treatment of Becker. We also expect CIRRUS‑HCM 12‑week Part D results for EDG‑7500 in HCM in the first half of 2026."
Koch added that the company’s robust balance sheet underpins its progress. "With a strong balance sheet, we continue to make great progress on our cardiac and skeletal muscle programs," he said. "Planning for success in GRAND CANYON, we are building the commercial infrastructure to support a potential launch of sevasemten in Becker."
The financial results underscore Edgewise’s investment‑heavy strategy. While the widening losses reflect continued spending on late‑stage clinical development, the substantial cash reserve and projected runway provide a cushion for the upcoming data releases that could unlock regulatory approvals and commercial opportunities. The company’s focus on muscular dystrophy and hypertrophic cardiomyopathy positions it to address significant unmet medical needs, and the forthcoming data will be closely watched by investors and analysts alike.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.